Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMG1 | Q96Q15 | 2/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924320 | 0.93 | SMG1 (0.39) | SMG1CDK1CDK2KMT2ACNR2 | |
| SCHEMBL6925038 | 0.89 | SMG1 (0.39) | SMG1CDK1CDK2KMT2ACNR2 | |
| SCHEMBL6923494 | 0.86 | CDK1 (0.38) | SMG1CDK1CDK2KMT2ACNR2 | |
| SCHEMBL6921614 | 0.85 | CDK1 (0.43) | SMG1CDK1CDK2KMT2ACNR2 | |
| SCHEMBL6923498 | 0.85 | CDK1 (0.39) | SMG1CDK1CDK2KMT2ACNR2 | |
| SCHEMBL6923470 | 0.84 | CDK1 (0.41) | SMG1CDK1CDK2KMT2APTPN11 | |
| SCHEMBL6924886 | 0.83 | ITGB2 (0.43) | SMG1CDK1CDK2PTPN11MAPT | |
| SCHEMBL6923488 | 0.80 | KDM4E (0.39) | SMG1CDK1CDK2KMT2APTPN11 | |
| SCHEMBL6927844 | 0.79 | HRH3 (0.43) | SMG1CDK1CDK2KMT2ACNR2 | |
| SCHEMBL6928029 | 0.79 | SMG1 (0.43) | SMG1CDK1CDK2KMT2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| US-6355635-B1 | IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY | PFIZER INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | SMG1 4380/4885CDK1 3513/4885CDK2 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.